Mobile integration has not been added to the site yet.

Anavex Life Sciences

Anavex Life Sciences (NASDAQ:AVXL) is a clinical stage biopharma company with a market cap of $1.07B, currently targeting Mild-to-Moderate Alzheimer’s Disease (AD) with its lead candidate Blarcamesine (ANAVEX 2-73). They published their latest set of clinical data, their Phase IIb/III trial data on 31 Oct 2024. The results headlined as positive news but are very questionable. Their MAA filing was recently accepted by the EMA, starting the clock on a 210 day review period, finishing on 19th July 2025. They also have another catalyst date on 13 Jan, where they are scheduled to present their Phase 2b/3 data at the JP Morgan Healthcare Conference.

9 Jan 2024